Literature DB >> 19861219

Brain-derived neurotrophic factor in patients with normal-tension glaucoma.

Alireza Ghaffariyeh1, Nazafarin Honarpisheh, Yadollah Shakiba, Sadollah Puyan, Tooraj Chamacham, Farzad Zahedi, Mojtaba Zarrineghbal.   

Abstract

PURPOSE: The aim of this study was to detect and measure brain-derived neurotrophic factor (BDNF) in the tears of normal subjects and patients with normal-tension glaucoma (NTG).
MATERIALS AND METHODS: Twenty patients with NTG as the case group and 20 normal subjects with the same age range as the control group were tested. The control group consisted of 16 men and 4 women, ranging in age from 40 to 75, without any apparent ocular or systemic disease. The case group consisted of 15 men and 5 women, ranging in age from 45 to 74. BDNF levels in tears were determined by enzyme-linked immunosorbent assay using monoclonal antibodies specific for BDNF (R&D Systems, Minneapolis, Minnesota).
RESULTS: The mean level of BDNF detected in the tears of the normal subjects was 77.09 +/- 4.84 ng/mL and the BDNF levels in the tears of case group were 24.33 +/- 1.48 ng/mL (P < 0.001).
CONCLUSION: We suggest that BDNF in the tears might be a useful biochemical marker for early detection of normal-tension glaucoma (NTG).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19861219     DOI: 10.1016/j.optm.2008.09.014

Source DB:  PubMed          Journal:  Optometry        ISSN: 1558-1527


  19 in total

1.  The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma.

Authors:  Mehmet Murat Uzel; Ufuk Elgin; Barış Boral; Muharrem Çiçek; Emine Şen; Burçin Şener; Pelin Yılmazbaş
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-07       Impact factor: 3.117

2.  Role of BDNF/TrkB pathway in the visual system: Therapeutic implications for glaucoma.

Authors:  B A Mysona; J Zhao; K E Bollinger
Journal:  Expert Rev Ophthalmol       Date:  2016-11-23

3.  BDNF and HSP gene polymorphisms and their influence on the progression of primary open-angle glaucoma in a Polish population.

Authors:  Alicja Nowak; Jacek P Szaflik; Mira Gacek; Karolina Przybylowska-Sygut; Anna Kamińska; Jerzy Szaflik; Ireneusz Majsterek
Journal:  Arch Med Sci       Date:  2014-09-05       Impact factor: 3.318

Review 4.  Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine.

Authors:  Suzanne Hagan; Eilidh Martin; Amalia Enríquez-de-Salamanca
Journal:  EPMA J       Date:  2016-07-13       Impact factor: 6.543

Review 5.  Synaptic Dysfunction in Alzheimer's Disease and Glaucoma: From Common Degenerative Mechanisms Toward Neuroprotection.

Authors:  Chiara Criscuolo; Carlotta Fabiani; Elisa Cerri; Luciano Domenici
Journal:  Front Cell Neurosci       Date:  2017-02-27       Impact factor: 5.505

6.  Exploring Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor Across Glaucoma Stages.

Authors:  Francesco Oddone; Gloria Roberti; Alessandra Micera; Anna Busanello; Stefano Bonini; Luciano Quaranta; Luca Agnifili; Gianluca Manni
Journal:  PLoS One       Date:  2017-01-09       Impact factor: 3.240

Review 7.  The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration.

Authors:  Marita Pietrucha-Dutczak; Marialaura Amadio; Stefano Govoni; Joanna Lewin-Kowalik; Adrian Smedowski
Journal:  Front Neurosci       Date:  2018-11-15       Impact factor: 4.677

Review 8.  Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma.

Authors:  Pawel Grieb; Anselm Jünemann; Marek Rekas; Robert Rejdak
Journal:  Front Aging Neurosci       Date:  2016-04-08       Impact factor: 5.750

Review 9.  Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration.

Authors:  Atsuko Kimura; Kazuhiko Namekata; Xiaoli Guo; Chikako Harada; Takayuki Harada
Journal:  Int J Mol Sci       Date:  2016-09-20       Impact factor: 5.923

10.  Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling.

Authors:  Andrew Osborne; Tasneem Z Khatib; Lalana Songra; Amanda C Barber; Katie Hall; George Y X Kong; Peter S Widdowson; Keith R Martin
Journal:  Cell Death Dis       Date:  2018-09-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.